Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...

The approval, which was granted to Roche’s Genentech unit, should offer patients living with SMA greater flexibility in how they manage their disease, the company said in a release. Back in 2020 ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...

Morgan Stanley initiated coverage of Roche (RHHBY) with an Equal Weight rating and CHF 305 price target The firm sees the end of Roche’s ...

A spokesman for Genentech said the drugmaker is taking time to understand any potential implications of executive orders and other actions by the new US administration. Roche’s programs in ...

The FDA has approved Roche’s Evrysdi (risdiplam ... head of global product development, Genentech, in a press release. “The Evrysdi tablet combines established efficacy with convenience, providing an ...

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...

February 12, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA ...

Assess today's live Roche Holding Ltd DRC (RHHBY) share price, performance and insights using our live OTC Markets: RHHBY stock exchange data. Analyse the historical data and Roche Holding Ltd DRC ...

With the approval, granted to Roche subsidiary Genentech, Evrysdi remains the only noninvasive disease-modifying therapy for spinal muscular atrophy (SMA), according to Genentech’s news release. The ...